Business Services Industry
Talbots Announces Third Quarter 2007 Sales Results
Business Wire, Nov 8, 2007
-Company Reconfirms Previously Announced Outlook for Fall Season
HINGHAM, Mass. -- The Talbots, Inc. (NYSE: TLB) today announced total Company sales for the thirteen weeks ended November 3, 2007 of $556 million, versus last year's reported sales of $569 million. By brand, retail store sales were $366 million for Talbots compared to $383 million last year, and $81 million for J. Jill compared to $77 million last year.
Consolidated comparable store sales declined 7.9% for the thirteen-week period, in line with the Company's previously revised expectations. This performance reflects greatly improved comparable store sales trends in the month of October for both brands, as compared to August/September. Comparable store sales for Talbots brand decreased 8.2% for the thirteen-week period, and for the J. Jill brand comparable store sales decreased 6.5%.
Consolidated direct marketing sales for the thirteen-week period were $109 million, including catalog and Internet, compared to $109 million last year.
Total Company year-to-date sales for the thirty-nine weeks ended November 3, 2007 were $1,702 million compared to $1,593 million reported for the thirty-nine weeks ended October 28, 2006. Retail store sales by brand were $1,146 million for Talbots and $242 million for J. Jill.
Consolidated comparable store sales declined 5.4% for the thirty-nine week period. By brand, comparable store sales for Talbots decreased 5.6% and J. Jill's comparable store sales declined 4.0%.
Consolidated direct marketing sales for the thirty-nine week period, including catalog and Internet, were $314 million.
Fall Season Outlook Reconfirmed
The Company reconfirmed its previously announced outlook for a fall season loss for the six-month period ending February 2, 2008 to be in the range of ($0.25) to ($0.35) per share, which includes approximately $0.16 of one-time expense related to executive compensation and professional consulting fees. This guidance assumes a consolidated third quarter loss per share in the range of ($0.20) to ($0.25), which includes approximately $0.07 per share of one-time expense related to executive compensation and professional consulting fees and a fourth quarter loss per share in the range of ($0.05) to ($0.10), including $0.09 per share of one-time expense related to executive compensation and professional consulting fees.
The Company plans to release its third quarter 2007 operating results on Tuesday, November 27, 2007 and will provide additional details at that time.
The Talbots, Inc. is a leading international specialty retailer and cataloger of women's, children's and men's apparel, shoes and accessories. The Company currently operates a total of 1,418 stores in 47 states, the District of Columbia, Canada and the U.K., with 1,153 stores under the Talbots brand name and 265 stores under the J. Jill brand name. Both brands target the age 35 plus customer population. Talbots brand on-line shopping site is located at www.talbots.com and the J. Jill brand on-line shopping site is located at www.jjill.com.
The foregoing contains forward-looking information within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may be identified by such forward-looking terminology as "expect," "look," "believe," "anticipate," "outlook," "will," "would," "target," "would yield," or similar statements or variations of such terms. All of the "outlook" information (including future revenues, future comparable sales, future earnings, future EPS, and other future financial performance or operating measures) constitutes forward-looking information.
Our outlook and other forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our Company which involve substantial risks and uncertainty, including assumptions and projections concerning integration costs, purchase-related accounting adjustments, acquisition synergies and, for each of our brands, store traffic, levels of store sales including meeting our internal plan and budget for regular-price selling and markdown selling for the indicated forward periods, and customer preferences. All of our outlook information and other forward-looking statements are as of the date of this release only. The Company can give no assurance that such outlook or expectations will prove to be correct and does not undertake or plan to update or revise any "outlook" information or any other forward-looking statements to reflect actual results, changes in assumptions, estimates or projections, or other circumstances occurring after the date of this release, even if such results, changes or circumstances make it clear that any projected results will not be realized.
Any public statements or disclosures by us following this release which modify or impact any of the outlook or other forward-looking statements contained in or accompanying this release will be deemed to modify or supersede such outlook or statements in or accompanying this release.
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Most Recent Business Articles
- Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones and the Initiation of a Clinical Trial of Ecopipam in Lesch-Nyhan Disease
- Emergence of “Femtomedicine” - New Frontier of Biomed Sciences - Reported at First Global Congress on Nano Medicine
- Research and Markets: Ethiopia Power Market Outlook to 2020
- Research and Markets: Orphan Drugs in Asia-Pacific: from Designation to Pricing, Funding & Market Access
- Research and Markets: Now You See It - TV Program Sponsorship & Product Placement in China
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FHM Features Anna Benson, Baseball's Hottest Wife
- Building a DNA database: the federal government has just enacted two bills related to DNA. The first would drive the collection of DNA from all infants. The second would attempt to prevent the DNA that is collected from being misused
- America's most wanted j-o-b-s - 10 hottest employment opportunities
- Developmental sequence in small groups


